Ultimo aggiornamento: agosto 17, 2026
Breve riassunto:
Le MSC sono state studiate per il trattamento di malattie epatiche e di malattie non epatiche. Le MSC hanno avuto successo nel trattamento di condizioni come la GVHD acuta resistente agli steroidi in pazienti sottoposti a trapianto di cellule staminali ematopoietiche e hanno anche dimostrato di migliorare il punteggio MELD nella malattia epatica allo stadio terminale. There were no severe side effects observed in using autologous MSCs as a treatment option. The outcome of the studies done so far have been positive and it is encouraged to study the use of MSCs as cell therapy for treating liver diseases.
The estimated rate of cirrhosis in HBV patients in Singapore is about 1.6% all'anno, rate of hepatocellular carcinoma is about 0.8% per year overall and 3.0% per year in cirrhotic patients. Knowing that there are not many options currently available for Liver Cirrhosis patients and that they have a poor prognosis with an average life expectancy of < 12 mesi, this study uses autologous MSCs to treat Liver Cirrhosis patients in Singapore. The objective of the study is to demonstrate that autologous bone marrow is safe to be used in patients with liver cirrhosis as well as demonstrate that bone marrow MSC may improve liver function and prolong patient survival.
Condition or disease Intervention/treatment Phase
Descrizione dettagliata:
Liver cirrhosis refers to extreme scarring of the liver, resulting in suboptimal function of the liver. Può derivare da una varietà di cause, ranging from hepatitis B and C infection, consumo eccessivo di alcol, autoimmune causes, fatty liver and others. Irrespective of the cause, once the liver becomes cirrhotic, it is a downhill course.
Liver cirrhosis is irreversible and most patients will progressively worsen over time. Once liver cirrhosis has reached the stage of decompensation, questo è, development of jaundice, ascite, sanguinamento da varici, hepatic encephalopathy and coagulopathy the two-year survival drops to about 50%.
The definitive treatment of decompensated cirrhosis is liver transplantation. While a liver transplantation is potentially curative, the high costs, lack of a donor, treatment-related mortality and the immunosuppression complications make this option possible only for a limited number of patients. The vast majority do not have an effective option at all, thus the need to develop alternative therapies. Various types of Stem Cells had been investigated as a regenerative therapy for liver cirrhosis. These stem cells include bone marrow mesenchymal stem cells (MSC), cellule mononucleate del midollo osseo (MNC) and peripheral CD34 positive cells. Some early studies have shown encouraging results in patients who had autologous bone marrow stem cell transplantation. There was improved liver function in these patients with cirrhotic livers.
The sponsor is proposing a study to look into the role of MSC therapy for patients with liver cirrhosis in Singapore. This will be a Phase I/II study with the main emphasis on the safety profile first. The trial will be conducted in compliance with the protocol, GCP and local regulatory requirement(S).
Revisione scientifica del caso
Ti piacerebbe capire se i programmi clinici sono attuali, recenti sviluppi della ricerca, o potrebbero esserlo gli approcci emergenti rilevante per la tua situazione individuale?
Invia la tua domanda al nostro team scientifico. La sede centrale di NBScience nel Regno Unito coordina le richieste attraverso la rete internazionale di centri medici, scienziati, e consulenti specializzati.
- Revisione delle informazioni fornite
- Informazioni rilevanti sulla ricerca e sul programma clinico
- Una risposta chiara focalizzata sulla tua situazione
Nessun obbligo. La tua domanda verrà esaminata in modo confidenziale.
Solo informazioni didattiche e di ricerca. Questo servizio no costituiscono un parere medico, diagnosi, prescrizione, o uno personalizzato raccomandazione terapeutica.
